Proposal of a new 18F-FDG PET/CT predictor of response in rectal cancer treated by neoadjuvant chemoradiation therapy and comparison with percist criteria

Clinical Nuclear Medicine

Volumn 38, Issue 10, 2013, Pages 795-797

  Maffione, Anna Margherita ^a   Ferretti, Alice ^a,b   Chondrogiannis, Sotirios ^a   Rampin, Lucia ^a   Marzola, Maria Cristina ^a   Grassetto, Gaia ^a   Capirci, Carlo ^c   Colletti, Patrick M ^d   Rubello, Domenico ^a  

^a Department of Imaging   (Italy)

^b Medical Physics Department   (Italy)

^c Santa Maria della Misericordia Hospital   (Italy)

^d UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Locally advanced rectal cancer; Neoadjuvant chemoradiotherapy; PERCIST; PET CT; Predictive; PREDIST; SUV; TRG

Indexed keywords

FLUORODEOXYGLUCOSE F 18; FLUOROURACIL; DIAGNOSTIC AGENT;

ACCURACY; ADJUVANT CHEMORADIOTHERAPY; ADULT; ADVANCED CANCER; ARTICLE; CANCER GRADING; CANCER PATIENT; DIAGNOSTIC TEST ACCURACY STUDY; FEMALE; HUMAN; HUMAN TISSUE; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MINIMAL RESIDUAL DISEASE; PERCIST CRITERIA; PREDICTIVE VALUE; PREDIST CRITERIA; PREOPERATIVE PERIOD; RECTUM CANCER; SCORING SYSTEM; SENSITIVITY AND SPECIFICITY; TREATMENT RESPONSE; TUMOR REGRESSION; ADJUVANT THERAPY; CHEMORADIOTHERAPY; COMPARATIVE STUDY; COMPUTER ASSISTED TOMOGRAPHY; PATHOLOGY; POSITRON EMISSION TOMOGRAPHY; RADIOGRAPHY; RECTUM TUMOR; SCINTISCANNING; TREATMENT OUTCOME; DIAGNOSTIC USE; RECTAL NEOPLASMS;

CHEMORADIOTHERAPY; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM, RESIDUAL; POSITRON-EMISSION TOMOGRAPHY; RECTAL NEOPLASMS; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 84897584286     PISSN: 03639762     EISSN: 15360229     Source Type: Journal    
DOI: 10.1097/RLU.0b013e3182a20153     Document Type: Article

References (19)

1. U.S. Cancer Statistics Working Group. United States Cancer Statistics: 1999Y 2007 Incidence and Mortality Web-Based Report. Atlanta (GA): Department of Health and Human Services, Centers for Disease Control and Prevention, and National Cancer Institute; 2010.
2. Bosset JF, Collette L, Calais G, et al. Chemotherapy with preoperative radiotherapy in rectal cancer. N Engl J Med. 2006;355:1114-1123.
3. De Paoli A, Chiara S, Luppi G, et al. Capecitabine in combination with preoperative radiation therapy in locally advanced, resectable, rectal cancer: a multicentric phase II study. Ann Oncol. 2006;17:246-251.
4. Graf W, Dahlberg M, Osman MM, et al. Short-term preoperative radiotherapy results in down-staging of rectal cancer: a study of 1316 patients. Radiother Oncol. 1997;43:133-137.
5. Rödel C, Martus P, Papadoupolos T, et al. Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer. J Clin Oncol. 2005;23:8688-8696.
6. Rosenberg R, Nekarda H, Zimmermann F, et al. Histopathological response after preoperative radiochemotherapy in rectal carcinoma is associated with improved overall survival. J Surg Oncol. 2008;97:8-13.
7. Medich D, McGinty J, Parda D, et al. Preoperative chemoradiotherapy and radical surgery for locally advanced distal rectal adenocarcinoma: pathologic findings and clinical implications. Dis Colon Rectum. 2001;44:1123-1128.
8. Habr-Gama A, Perez RO, Nadalin W, et al. Long-term results of preoperative chemoradiation for distal rectal cancer correlation between final stage and survival. J Gastrointest Surg. 2005;9:90-99.
9. Valentini V, Coco C, Cellini N, et al. Ten years of preoperative chemoradiation for extraperitoneal T3 rectal cancer: acute toxicity, tumor response, and sphincter preservation in three consecutive studies. Int J Radiat Oncol Biol Phys. 2001;51:371-383.
10. 18F-FDG PET in patients with locally advanced rectal cancer previously treated with neoadjuvant radiochemotherapy. AJR Am J Roentgenol. 2006;187: W202-W208.
11. Wahl RL, Jacene H, Kasamon Y, et al. From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors. J Nucl Med. 2009; 50(suppl 1):122S-150S.
12. Costelloe CM, Chuang HH, Madewell JE, et al. Cancer response criteria and bone metastases: RECIST 1.1, MDA and PERCIST. J Cancer. 2010;1:80-92.
13. Maffione AM, Ferretti A, Grassetto G, et al. Fifteen different (18)F-FDG PET/CT qualitative and quantitative parameters investigated as pathological response predictors of locally advanced rectal cancer treated by neoadjuvant chemoradiation therapy. Eur J Nucl Med Mol Imaging. 2013;40:853-864.
14. Maffione AM, Ferretti A, Vinjamuri S, et al. The PERCIST criteria: an insightful appraisal. Nucl Med Commun. 2013;34:619-620.
15. Capirci C, Rampin L, Erba PA, et al. Sequential FDG-PET/CT reliably predicts response of locally advanced rectal cancer to neo-adjuvant chemo-radiation therapy. Eur J Nucl Med Mol Imaging. 2007;34:1583-1593.
16. Capirci C, Valvo F, Salviato S. Concurrent boost radiotherapy as preoperative treatment for locally advanced rectal carcinoma: a new beam arrangement. Tumori. 2002;88:325-330.
17. Capirci C, Polico C, Mandoliti G. Dislocation of small bowel volume within box pelvic treatment fields, using the new "Up Down Table" device. Int J Radiat Oncol Biol Phys. 2002;88:325-330.
18. Quirke P, Dixon MF. The prediction of local recurrence in rectal adenocarcinoma by histopathological examination. Int J Colorectal Dis. 1988;3:127-131.
19. Mandard AM, Dalibard F, Mandard JC, et al. Pathologic assessment of tumor regression after preoperative CRT of esophageal carcinoma. Clinicopathologic correlations. Cancer. 1994;73:2680-2686.